GIBSON DUNN

Gibson Dunn Advised Dianthus Therapeutics on $288 Million Offering of Common Stock and Pre-Funded Warrants

Firm News | September 12, 2025

Gibson Dunn advised Dianthus Therapeutics, Inc., a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, on its $288 million offering of common stock and pre-funded warrants.

Our corporate team was led by partners Ryan Murr, Branden Berns, and Melanie Neary and included associates Nicholas Linke, Jasmine Vitug, and Lauren Guzman.

Related People

Ryan A. Murr

Branden C. Berns

Melanie E. Neary

Nicholas G. Linke

Jasmine L. Vitug

Lauren Guzman

Related Capabilities

Life Sciences

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**